KMID : 0338420190340040885
|
|
Korean Journal of Internal Medicine 2019 Volume.34 No. 4 p.885 ~ p.893
|
|
Clinical significance of rituximab infusion-related reaction in diffuse large B-cell lymphoma patients receiving R-CHOP
|
|
Cho Kyoung-Min
Keam Bhum-Suk Ha Hye-Rim Kim Mi-So Jung Jae-Woo Song Woo-Jung Kim Tae-MIn Jeon Yoon-Kyung Kang Hye-Ryun Kim Dong-Wan Kim Chul-Woo Heo Dae-Seog
|
|
Abstract
|
|
|
Background/Aims: This study was to evaluate the clinical significance of infusion-related reaction (IRR) of rituximab in diffuse large B-cell lymphoma (DLBCL) patients who received R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone) as a first-line chemotherapy.
Methods: The medical records of 326 patients diagnosed with DLBCL were re trospectively analyzed. Both doctor¡¯s progress records and nursing records were reviewed. IRR was graded according to the National Cancer Institute Common Terminology Criteria.
Results: IRR was not associated with overall survival (OS) or progression-free survival (PFS) of DLBCL patients as compared to those who did not have IRR (OS: median 78.0 months vs. 69.0 months, p = 0.700; PFS: median 65.4 months vs. 64.0 months, p = 0.901). IRR grade did not affect OS or PFS. B symptoms was independently associated with IRR (hazard ratio [HR], 1.850; 95% confidence interval [CI], 1.041 to 3.290; p = 0.036). Further, bone marrow involvement was independently associated with re-IRR (HR, 4.904; 95% CI, 0.767 to 3.118; p = 0.029).
Conclusions: Our study shows that IRR of rituximab is not associated with OS or PFS of DLBCL patients who received R-CHOP. Furthermore, our study suggests a need for more careful observation for IRR in patients with B symptoms or bone marrow involvement.
|
|
KEYWORD
|
|
Infusion-related reaction, Rituximab, Lymphoma, large B-cell, diffuse, Prognosis, Characteristics
|
|
FullTexts / Linksout information
|
|
|
|
Listed journal information
|
|
|
|